At Kainova Therapeutics, our work is driven by one pivotal question: how can science deliver better outcomes for patients with underserved medical needs? The answer is rooted in our commitment to bold science, to collaboration, and to patients who need new treatment options. We focus on breakthrough GPCR-modulating therapies in immuno-oncology and inflammation, built on decades of scientific and medical expertise from our leadership team, and our proprietary, validated approach. We foster a culture where scientific excellence and human purpose go hand in hand.

Profile

Social Media

Kainova Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Sean MacDonald

Chief Financial Officer

Stanislas Malmezat

Chief Medical Officer

Jean-Marie Cuillerot

Chief Scientific Officer

Stephan Schann

Vice President

Nathalie Lenne

VP - Bus. Development

Marjorie Sidhoum

VP - Human Resources

Aurélie Maisner

VP - R & D

Laurent Sabbagh

Browse more venture capital transactions:

Prev: 2/10/2026: Vesiro venture capital transaction
Next: 2/10/2026: Somethings venture capital transaction

Share this article

News on VC Transactions

We record all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary